Because the products can be administered intravenously, the HepaGam B enables healthcare providers to treat HBsAg-postive liver transplant patients prophylactically to prevent hepatitis B recurrence following transplantation.

"Our customers rely on BDI to offer innovative products and therapies as they become available," said Richard Gaton, President of BDI. "We are excited to be able to complement our hyper-immune product line with the addition of HepaGam B to our product portfolio."

BDI offers an extensive line of hyper-immune products, including immune globulins administered for the post-exposure prophylactic treatment of Hepatitis A, Hepatitis B, Rabies, Rh Sensitization, and Tetanus.

HepaGam B is a sterilized solution of purified gamma globulin (IgG) fraction derived from human plasma containing antibodies to hepatitis B surface antigen. It is manufactured by Cangene and distributed by Apotex. The product is manufactured from human plasma obtained from suitable healthy donors who have been vaccinated with a recombinant hepatitis B vaccine. The plasma from these donors contains high levels of anti-hepatitis B antibodies, which are purified to make HepaGam B. -Blood Diagnosis, Inc.